Boston Scientific shares fell 2.3% in pre-market trading after the company issued a formal notice that the cybersecurity incident discovered on August 25 is now expected to materially affect its third-quarter and full-year 2026 financial results. In the filing, the company said it is unlikely to achieve the net sales growth and adjusted EPS guidance it had provided investors earlier.
The firm's statement, reported by Bloomberg, contrasts with its earlier public comments that the financial impact of the breach had not yet been determined. That change in tone - from uncertainty to an anticipated material effect - prompted renewed investor scrutiny and selling pressure ahead of the market open.
Analyst activity has already been pressuring the shares this year. Argus Research cut its rating on the stock from Buy to Hold, highlighting growth concerns tied to the Watchman device and the U.S. electrophysiology business. Following the company’s second-quarter results and the initial disclosure of the cyberattack, Baird, JPMorgan, and Bank of America each reduced their price targets for the company.
TD Cowen has been a relative outlier among brokerages, maintaining a Buy rating and a $56 price target. In its update, TD Cowen pointed to progress in restoring distribution, noting in a September 5 update that the company’s major distribution centers were processing and shipping products at or above normal levels. However, that operational improvement appears to have been overshadowed by Boston Scientific’s formal warning about its financial outlook.
The broader market provided little solace. The S&P 500 was modestly lower, the Dow Jones Industrial Average was down by a larger margin, and the NASDAQ was nearly flat, reflecting a generally cautious tone across U.S. equities. The medtech sector itself has been muted after peers including Abbott and Medtronic navigated their own cybersecurity incidents in 2026, contributing to subdued sentiment for medical device companies.
Taken together, the combination of a formal guidance miss warning tied directly to the cyberattack, an earlier analyst downgrade, and a soft market backdrop has produced a confluence of selling pressure on Boston Scientific. The stock is trading substantially below its 52-week high of $109.50 and closer to its 52-week low of $42.20.
Investors will be watching for further company disclosures that clarify the magnitude and duration of the financial impact, as well as any operational or distribution disruptions that could influence near-term revenue recognition and adjusted earnings. For now, the formal guidance withdrawal represents a significant development that changes the risk profile for the company’s 2026 outlook.
Summary
Boston Scientific warned that the cyberattack discovered on August 25 will likely have a material effect on Q3 and full-year 2026 results and said it is unlikely to meet prior net sales growth and adjusted EPS guidance. The disclosure reversed an earlier stance of undetermined financial impact and triggered pre-market selling pressure.
Key points
- The company announced a material financial impact from the August 25 cyberattack, and withdrew its prior sales and adjusted EPS guidance.
- Analyst actions have included Argus downgrading the shares to Hold and several banks trimming price targets; TD Cowen reiterated a Buy rating with a $56 target while noting restored distribution centers as of September 5.
- The wider market and recent cybersecurity incidents across the medtech sector, including at peers Abbott and Medtronic, have contributed to subdued investor sentiment.
Risks and uncertainties
- The extent and duration of the financial impact from the cyberattack remain unclear, creating earnings and revenue risk for the medtech sector.
- Ongoing analyst pressure and trimmed price targets may weigh on investor confidence in Boston Scientific and related medical device names.
- A cautious broader market environment and recent sector-wide cybersecurity issues could prolong subdued performance for medtech equities.